Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irx-4204. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA known ✓ | P19793 | 20/20 | 1.00 |
| ▸ | RXRG known ✓ | P48443 | 12/20 | 1.00 |
| ▸ | RXRB known ✓ | P28702 | 10/20 | 1.00 |
| ▸ | RARB | P10826 | 8/20 | 1.00 |
| ▸ | RARG | P13631 | 8/20 | 1.00 |
| ▸ | RARA | P10276 | 3/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irx-4204 SCHEMBL8330929 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL6230860 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL3437269 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL29357376 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL18811985 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL24767436 | 1.00 | RXRA (1.00) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244484 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244477 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244476 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG | |
| Irx-4204 SCHEMBL27244482 | 0.99 | RXRA (0.98) | RXRARXRGRXRBRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024484-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER | DUKE UNIVERSITY (US) | 2025-01-30 | — | — | WO | claimed |
| CN-117887658-A | Method for differentiating human pluripotent stem cells into natural killer cells and application thereof | 浙江霍德生物工程有限公司 | 2024-04-16 | — | — | CN | claimed |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-10-10 | — | — | US | claimed |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-08-29 | — | — | US | claimed |
| CN-115671292-A | Receptor selective retinoid and rexinoid compounds and immunomodulators for cancer immunotherapy | IO治疗公司 | 2023-02-03 | — | — | CN | claimed |
| CN-109310763-B | Receptor selective retinoid and rexinoid compounds and immunomodulators for cancer immunotherapy | IO治疗公司 | 2022-10-21 | — | — | CN | claimed |
| WO-2025024484-A1 | COMPOSITIONS AND METHODS FOR TREATING BLOOD CANCER | DUKE UNIVERSITY (US) | 2025-01-30 | — | — | WO | disclosed |
| CN-117887658-A | Method for differentiating human pluripotent stem cells into natural killer cells and application thereof | 浙江霍德生物工程有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116370491-A | Use of antisense oligonucleotides in treating coronavirus related diseases | 北京瑞博开拓医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | Io Therapeutics, Inc. (US) | 2023-05-16 | — | — | US | disclosed |
| CN-115916165-A | Antiandrogen or androgen receptor antagonists for the treatment of viral respiratory infections | 苏州开拓药业股份有限公司 | 2023-04-04 | — | — | CN | disclosed |
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | JIANG GUANG LIANG | 2007-08-09 | — | — | US | disclosed |
| US-7019034-B2 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | ALLERGAN, INC. (US) | 2006-03-28 | — | — | US | disclosed |
| US-6887896-B1 | 7-[(7-Alkoxy)-chrom-3-en-6-yl]-heptatrienoic acid and 7-[(3-alkoxy)-5,6-dihydronaphthalen-2-yl]-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-20040198825-A1 | 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | ALLERGAN, INC. | 2004-10-07 | — | — | US | disclosed |
| US-20040147611-A1 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | ALLERGAN, INC. | 2004-07-29 | — | — | US | disclosed |
| US-6759547-B1 | REDUCES SERUM GLUCOSE AND SERUM TRIGLYCERIDE LEVELS IN DIABETIC MAMMALS WITHOUT THE UNDESIRABLE PROPERTIES OF REDUCING SERUM THYROXINE LEVELS AND TRANSIENTLY RAISING TRIGLYCERIDE LEVELS | ALLERGAN, INC. | 2004-07-06 | — | — | US | disclosed |
| US-6734193-B1 | REDUCE SERUM GLUCOSE AND SERUM TRIGLYCERIDE LEVELS IN DIABETIC MAMMALS WITHOUT THE UNDESIRABLE PROPERTIES OF REDUCING SERUM THYROXINE LEVELS AND TRANSIENTLY RAISING TRIGLYCERIDE LEVELS | ALLERGAN, INC. | 2004-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737996-B2 | Immunomodulatory and differentiating function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RXRA 1/4885RXRG 2/4885RXRB 3/4885 |
| US-11779558-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRG, RXRA, RXRB | RXRA 2/4885RXRG 1/4885RXRB 3/4885 |
| US-20040147611-A1 | Compositions and methods for reducing serum glucose and triglyceride levels in diabetic mammals | RXRA, RXRB, RXRG | RXRA 1/4885RXRG 3/4885RXRB 2/4885 |
| US-11648223-B2 | Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy | RXRA, RXRG, RXRB | RXRA 1/4885RXRG 2/4885RXRB 3/4885 |
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | RXRA, RXRG, RXRB | RXRA 1/4885RXRG 2/4885RXRB 3/4885 |
| US-20040198825-A1 | 5,6,7,8-Tetrahydronaphthalen-2-yl-7-fluoroalkyl-heptatrienoic acid derivatives having serum glucose reducing activity | TPO, TTR, FABP1 | RXRA 145/4885RXRG 265/4885RXRB 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.